Introducing Prof. Dr. Salwa Ahmed Elgebaly

- CEO, Nour Heart, Inc. Established in Hartford, Connecticut, USA
- Professor, University of Connecticut Faculty of Medicine (Adj.), Farmington, Connecticut, USA

The aim of Nour Heart is to develop Cyclocreatine Phosphate as a new cardioprotective drug for patients with ischemic heart disease.
She is the Inventor of nine (9) Patents Issued by the U.S. Patent Office and two pending applications.

In 2005, Dr. Elgebaly initiated and was instrumental in implementing the establishment of the first Clinical Research Center (CRC) at Alexandria Faculty of Medicine to conduct all phases of FDA-regulated clinical trials. The CRC celebrated its tenth year in 2016 as the best in Egypt and Middle East according to international pharmaceutical companies. Dr. Elgebaly serves as a volunteer Consultant in the CRC.

She has been most honored by invitations to present her new and unique work from:

▪ Nobel Prize Winner in Medicine, Professor Sir John Vane, London, United Kingdom.
▪ Nobel Prize Winner in Medicine, Professor R. Levi Montalcini, Rome, Italy.
▪ Professor Sir Dr. Magdy Yacoub in London, United Kingdom.

Prof. Dr. Salwa Elgebaly is the Inventor of nine (9) Patents Issued by the U.S. Patent Office and two pending applications.

Nour Heart, Inc. Is Granted Orphan Drug Designation by U.S. Food and Drug Administration (FDA) for Prevention of Cardiac Ischemic Injury in Heart Transplantation

Nour Heart, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cyclocreatine Phosphate for the prevention of ischemic injury to enhance cardiac graft recovery and survival in heart transplantation (DRU-2015-4951).